Shimoyama Yoshihito, Hirabayashi Kazuhiro, Matsumoto Hiroatsu, Sato Toshitsugu, Shibata Shoji, Inoue Hideo
Research Laboratory, Minophagen Pharmaceutical Co., Ltd, 2-2-3 Komatsubara, Zama-shi, Kanagawa 228-0002, Japan.
J Pharm Pharmacol. 2003 Jun;55(6):811-7. doi: 10.1211/002235703765951429.
The purpose of this study was to examine the structure and activity relationships of glycyrrhetinic acid derivatives on the inhibition of hepatic and renal 11beta-hydroxysteroid dehydrogenases (HSDs) in rats. Furthermore, we explored whether inflammatory effect of the derivatives is involved in the inhibition of 11beta-HSD activity. 18beta-Glycyrrhetinic acid (Ia) potently inhibited 11beta-HSD activity of hepatic (IC50 (concentration giving 50% inhibition of cortisone production) = 0.09 microM) and renal (IC50 = 0.36 microM) homogenate. The inhibitory effect of 18beta-glycyrrhetol (Id) modified at the 30-position of glycyrrhetinic acid was weaker than that of glycyrrhetinic acid itself. 18beta-24-Hydroxyglycyrrhetinic acid (Ie), oxidized at the 24-position, remarkably reduced the inhibitory activity for both enzymes. 18beta-11-Deoxoglycyrrhetinic acid (IIc) showed the same inhibitory effect as glycyrrhetinic acid on hepatic 11beta-HSD activity, but less effect on renal 11beta-HSD activity. Furthermore, the inhibitory activity of 18beta-deoxoglycyrrhetol (IIa), modified at the 11- and 30-position, was markedly decreased. Dihemiphthalate derivatives (IIb, IIIb and IVb) of deoxoglycyrrhetol (IIa), 18beta-olean-9(11), 12-diene-3beta, 30-diol (IIIa) and olean-11, 13(18)-diene-3beta, 30-diol (IVa), which are anti-inflammatory agents, also showed weak inhibition against both hepatic and renal 11beta-HSDs. While glycyrrhetinic acid (200 mg kg(-1), p.o.) significantly inhibited 11beta-HSD activity in rat liver and kidney at 3 h after administration, compound IVb (100 mg kg(-1), p.o.) had no effect on either enzyme activity. In addition, the circulating corticosterone level was slightly increased by glycyrrhetinic acid but not by compound IVb. These results suggest that the anti-inflammatory effects of compound IVb, derived from glycyrrhetinic acid, are not due to accumulation of steroids induced by the inhibition of 11beta-HSD activity. Our data also showed that the 11-, 24- and 30-positions of glycyrrhetinic acid may play important roles in the differential inhibitory effects on 11beta-HSD isozyme activity.
本研究的目的是考察甘草次酸衍生物对大鼠肝脏和肾脏11β-羟基类固醇脱氢酶(HSDs)抑制作用的构效关系。此外,我们还探讨了这些衍生物的抗炎作用是否参与了对11β-HSD活性的抑制。18β-甘草次酸(Ia)能有效抑制肝脏(IC50(使可的松生成抑制50%的浓度)=0.09微摩尔)和肾脏(IC50 = 0.36微摩尔)匀浆的11β-HSD活性。在甘草次酸30位修饰的18β-甘草醇(Id)的抑制作用比甘草次酸本身弱。在24位氧化的18β-24-羟基甘草次酸(Ie)显著降低了对两种酶的抑制活性。18β-11-去氧甘草次酸(IIc)对肝脏11β-HSD活性的抑制作用与甘草次酸相同,但对肾脏11β-HSD活性的作用较小。此外,在11位和30位修饰的18β-去氧甘草醇(IIa)的抑制活性明显降低。去氧甘草醇(IIa)、18β-齐墩果-9(11),12-二烯-3β,30-二醇(IIIa)和齐墩果-11,13(18)-二烯-3β,30-二醇(IVa)的二半邻苯二甲酸酯衍生物(IIb、IIIb和IVb)作为抗炎剂,对肝脏和肾脏11β-HSDs也显示出较弱抑制作用。甘草次酸(200毫克·千克-1,口服)在给药后3小时能显著抑制大鼠肝脏和肾脏的11β-HSD活性,而化合物IVb(100毫克·千克-1,口服)对两种酶活性均无影响。此外,甘草次酸能使循环皮质酮水平略有升高,但化合物IVb则无此作用。这些结果表明,源自甘草次酸的化合物IVb的抗炎作用并非由于抑制11β-HSD活性导致的类固醇蓄积。我们的数据还表明,甘草次酸的11位、24位和30位可能在对11β-HSD同工酶活性的差异抑制作用中起重要作用。